Patents by Inventor Weiming Fan
Weiming Fan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117391Abstract: Provided is an engineered bacterium for producing nervonic acid and/or grease. The genome of the engineering bacterium is integrated with an expression cassette expressing a protein encoded by 3-ketoacyl-CoA synthase (KCS) gene and/or an exterase gene.Type: ApplicationFiled: November 18, 2021Publication date: April 11, 2024Applicants: QINGDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY, CHINESE ACADEMY OF SCIENCES, ZHEJIANG ZHENYUAN BIOTECH CO., LTD.Inventors: Shian Wang, Jianchang Ruan, Fuli Li, Hang Su, Weiming Fan, Xingfeng Han, Ziyue Meng, Penghui Shi
-
Patent number: 11933133Abstract: A technique facilitates actuation of a packer to a sealing and gripping position along a borehole. The packer includes a packer element structure mounted about a center structure. The packer element structure includes a sealing element mounted along an expandable base such that the sealing element may be radially expanded. Additionally, the packer includes an actuator member connected to a portion of the packer element structure via a release mechanism, e.g. a shear member. A plurality of slips may be located on the actuator member such that linear movement of the actuator member causes successive movement of the packer sealing element and then the slips in the radially outward direction. The packer may be constructed such that this sequential setting motion creates a jarring effect to ensure the slips securely bite into the surrounding wellbore surface, e.g. casing surface.Type: GrantFiled: October 20, 2020Date of Patent: March 19, 2024Assignee: SCHLUMBERGER TECHNOLOGY CORPORATIONInventors: Farhan Ahmed Omer, Susan Wu, Thomas Eric Dudley, Yiming Fan, Weiming Lan, Nitin Verroju
-
Patent number: 11692178Abstract: A genetically engineered bacterium includes a genome of the Eschericia coli and a mutant encoding gene hisG* of a Corynebacterium glutamicum ATP phosphoribosyl transferase HisG on the genome, and the gene hisG* is strongly expressed to enhance activity of a key enzyme HisG for histidine synthesis. The gene hisG* has a nucleotide sequence as shown in SEQ ID NO: 1; a copy number of histidine operon genes hisDBCHAFI of the Eschericia coli is further increased on the genome to enhance a terminal synthetic route of histidine; an encoding gene lysE from an arginine/lysine transportprotein of the Corynebacterium glutamicum is further integrated to the genome and strongly expressed to promote the intracellular histidine secrete to the extracellular space; and an encoding gene rocG of glutamate dehydrogenase of Bacillus subtilis is further integrated to the genome and strongly expressed to promote generation of histidine.Type: GrantFiled: June 18, 2021Date of Patent: July 4, 2023Assignees: ZHEJIANG ZHENYUAN BIOTECH CO., LTD., Tianjin University of Science and TechnologyInventors: Xixian Xie, Weiming Fan, Heyun Wu, Wei Jiang, Daoguang Tian, Yanna Chen, Yue Zhang, Jianqing Tu
-
Patent number: 11603545Abstract: The present invention discloses an engineering yeast strain for producing nervonic acids. The yeast strain over-expresses the genes related to enzymes required in a synthetic process of long-chain unsaturated fatty acids, such as fatty acid elongase, desaturase, diacylglycerol acyltransferase and the like, and optionally, further adjusts and controls the synthesis and decomposition route of triglyceride, the synthesis and decomposition route of sphingomyelin, and the synthesis and decomposition route and the oxidation-reduction balanced route of lipid subcell levels. The recombinant yeast strain can produce microorganism oil; and the content of the prepared nervonic acids accounts for 39.6% of the total fatty acids.Type: GrantFiled: April 8, 2019Date of Patent: March 14, 2023Assignees: ZHEJIANG ZHENYUAN BIOTECH CO. LTD., QINDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Fuli Li, Shian Wang, Weiming Fan, Huimin Meng, Kai Zhang, Jiaxin Li
-
Publication number: 20220403348Abstract: A genetically engineered bacterium includes a genome of the Eschericia coli and a mutant encoding gene hisG* of a Corynebacterium glutamicum ATP phosphoribosyl transferase HisG on the genome, and the gene hisG* is strongly expressed to enhance activity of a key enzyme HisG for histidine synthesis. The gene hisG* has a nucleotide sequence as shown in SEQ ID NO: 1; a copy number of histidine operon genes hisDBCHAFI of the Eschericia coli is further increased on the genome to enhance a terminal synthetic route of histidine; an encoding gene lysE from an arginine/lysine transportprotein of the Corynebacterium glutamicum is further integrated to the genome and strongly expressed to promote the intracellular histidine secrete to the extracellular space; and an encoding gene rocG of glutamate dehydrogenase of Bacillus subtilis is further integrated to the genome and strongly expressed to promote generation of histidine.Type: ApplicationFiled: June 18, 2021Publication date: December 22, 2022Applicants: ZHEJIANG ZHENYUAN BIOTECH CO., LTD., Tianjin University of Science and TechnologyInventors: Xixian XIE, Weiming FAN, Heyun WU, Wei JIANG, Daoguang TIAN, Yanna CHEN, Yue ZHANG, Jianqing TU
-
Publication number: 20210032665Abstract: The present invention discloses an engineering yeast strain for producing nervonic acids. The yeast strain over-expresses the genes related to enzymes required in a synthetic process of long-chain unsaturated fatty acids, such as fatty acid elongase, desaturase, diacylglycerol acyltransferase and the like, and optionally, further adjusts and controls the synthesis and decomposition route of triglyceride, the synthesis and decomposition route of sphingomyelin, and the synthesis and decomposition route and the oxidation-reduction balanced route of lipid subcell levels. The recombinant yeast strain can produce microorganism oil; and the content of the prepared nervonic acids accounts for 39.6% of the total fatty acids.Type: ApplicationFiled: April 8, 2019Publication date: February 4, 2021Inventors: Fuli LI, Shian WANG, Weiming FAN, Huimin MENG, Kai ZHANG, Jiaxin LI
-
Patent number: 10772331Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: May 23, 2019Date of Patent: September 15, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Patent number: 10744136Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.Type: GrantFiled: November 4, 2019Date of Patent: August 18, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bharathi Pandi, Joe B. Perales, Weiming Fan
-
Publication number: 20200138811Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.Type: ApplicationFiled: November 4, 2019Publication date: May 7, 2020Inventors: Jason D. SPEAKE, Bharathi PANDI, Joe B. PERALES, Weiming FAN
-
Publication number: 20190274305Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Patent number: 10342234Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: September 6, 2018Date of Patent: July 9, 2019Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Publication number: 20190000085Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: September 6, 2018Publication date: January 3, 2019Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Patent number: 10092001Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: December 21, 2017Date of Patent: October 9, 2018Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Publication number: 20180116223Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: December 21, 2017Publication date: May 3, 2018Inventors: Jason D. SPEAKE, Joe B. PERALES, Weiming FAN, Solene Clarisse ROLLAND
-
Patent number: 9883674Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: May 24, 2017Date of Patent: February 6, 2018Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solene Clarisse Rolland
-
Publication number: 20170258089Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: May 24, 2017Publication date: September 14, 2017Inventors: Jason D. Speake, Joe B. PERALES, Weiming FAN, Solene Clarisse ROLLAND
-
Patent number: 9686991Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: GrantFiled: July 15, 2016Date of Patent: June 27, 2017Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solène Clarisse Rolland
-
Publication number: 20160324156Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: July 15, 2016Publication date: November 10, 2016Inventors: Jason D. SPEAKE, Joe B. PERALES, Weiming FAN, Solène Clarisse ROLLAND
-
Publication number: 20160205936Abstract: The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.Type: ApplicationFiled: January 14, 2016Publication date: July 21, 2016Inventors: Jason D. Speake, Joe B. Perales, Weiming Fan, Solène Clarisse Rolland
-
Patent number: 8614221Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: March 10, 2010Date of Patent: December 24, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu